Quantcast
Last updated on April 18, 2014 at 9:00 EDT

Latest Small interfering RNA Stories

2012-11-27 08:28:00

LA JOLLA, Calif., Nov. 27, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Victor Knopov, Ph.D. to its executive management team as Vice President, Pharmaceutical Development. Dr. Knopov joined Regulus from Nitto Denko Technical Corporation where he served as Director, Chemistry Manufacturing Control since 2010. "Victor...

2012-11-05 04:21:49

LONDON, November 5, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading RNA interference (RNAi) therapeutics company, today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance indicating that it will grant patents based on two applications: 12/986,389 and 13/230,084. These cover respectively interfering RNA molecules and lipid complexes used in drug delivery. The claims allowed on interfering RNA molecules cover any...

2012-10-15 03:23:16

LONDON, October 15, 2012 /PRNewswire/ -- Silence Therapeutics plc has appointed Tim Freeborn, 53, as its finance director. A chartered accountant, he joined the company from Xcap Securities where he was head of research. Tim Freeborn said: 'Silence's area of biotech is moving incredibly quickly. The company could play a big role and I'm delighted to be joining at this time.' No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules....

2012-09-17 22:21:05

LONDON, September 18, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Michael Khan to its board of directors as Chief Medical Adviser. Dr Michael Khan BSc, MBBS, PhD, FRCP is an Associate Professor of Medicine at the University of Warwick and a Consultant Physician at University Hospitals. He trained in medicine at Guy's and King's in London and completed specialist...

2012-09-09 22:24:15

LONDON, September 10, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury. Atu111 targets the endothelial expression of Angiopoietin-2 (Ang-2), an antagonistic...

2012-08-30 06:24:31

CARLSBAD, Calif., Aug. 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of two papers in the journal Cell demonstrating that single-stranded short interfering RNA (ss-siRNA) molecules distributed broadly, activated the RNA interference (RNAi) pathway and reduced expression of targeted genes in animal models. The RNAi pathway is a mechanism that can be used to inhibit expression of genes. The RNAi pathway has typically been engaged by short...

2012-08-01 22:20:53

LONDON, August 2, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces that the New Shares issued in connection with the Subscription, Open Offer and Convertible Loan Note have today been admitted to trading on AIM. In addition, as set out in the Circular to shareholders...

2012-07-24 02:28:37

SANTA CRUZ, Calif., July 24, 2012 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, announced the publication of a study reporting the mechanism of action of its sshRNAs, the class of molecules that forms the basis of the company's therapeutic platform. sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs through an RNA interference (RNAi) mechanism. In...

2012-06-28 20:36:14

Steve Moose, an associate professor of maize functional genomics at the University of Illinois and his graduate student Wes Barber think they may have discovered a new source of heterosis, or hybrid vigor, in maize. They have been looking at small RNAs (sRNAs), a class of double-stranded RNA molecules that are 20 to 25 nucleotides in length. “Hybrid vigor” refers to the increased vigor or general health, resistance to disease, and other superior qualities arising from the...

2012-06-25 02:26:44

GAITHERSBURG, Md., June 25, 2012 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has been awarded another NIH SBIR (Small Business Innovation Research) grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation. This funding will further enhance the company's effort for perfection of its nanoparticle-based siRNA delivery systems and speed up the IND enabling studies for...